Back to news

MEDS press release

RTPR•19/11/2026•16:11 ET
0

Key Highlights

  • ➤DataMEDS agreed to acquire Todos Medical assets, subject to Court Approval
  • ➤Assets include TBIA blood tests for breast and colorectal cancer
  • ➤TBIA platform holds U.S. and European patents through at least 2034
  • ➤TBIA tests are not FDA-cleared, approved, or commercially available in the U.S.
  • ➤DataMEDS plans Helomics validation work toward commercial launch and FDA process

Expert Statements

Gerald Commissiong, Interim Co-CEO of DataMEDS

“The TBIA Cancer AI blood testing platform is a technology that was ahead of its time and now has the opportunity to truly flourish in the AI era.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“To be able to use a single vial of blood, perform a single data capture experiment in the lab and produce results that can help detect multiple types of cancer from that one blood test is truly transformative.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“This has the potential to make cancer detection not only less expensive to deploy on a per-cancer-diagnosis basis than existing liquid biopsy and other cancer screening tests, but also more clinically useful because this technology digitizes the immune system and as such may be able to identify and distinguish the body's response to cancer, even at the earliest carcinoma in situ stage.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“Earlier detection could open the possibility of its use in routine annual blood testing paradigms that would allow patients to be recommended for confirmatory imaging and biopsy testing much earlier in the disease course where cancers are typically significantly more likely to respond to treatment.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“We look forward to implementing this technology at our Helomics Cancer AI laboratory in Pittsburgh, Penn., where we will work with our emerging oncologist network to source blood samples, under IRB-approved protocols and with patient consent, from patients whose treating physicians are sending in tumor biopsies for the ChemoFx® Assay evaluation, that has been granted two unique CPT codes and has begun to receive coverage decisions, helping us to generate revenue while also generating the necessary data to validate the TBIA Cancer AI blood test to support eventual commercial launch as a Laboratory Developed Test and to advance it through the U.S. Food & Drug Administration (FDA) regulatory process thereafter.”

TAMPA, FL / ACCESS Newswire / November 19, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMeds AI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare technology company that integrates its physical pharmaceutical, laboratory and telemedicine infrastructures with its EinsteinRx™ Healthcare AI technology-powered digital platform, today announced that it has agreed to acquire certain assets from the estate of Todos Medical Ltd., including its Cancer Artificial Intelligence ("Cancer AI") Total Biochemical Infrared Analysis ("TBIA") blood tests for breast cancer (TM-B1 and TM-B2) (link) and colorectal cancer (TM-C1) (link), originally developed at Ben Gurion University (BGU) in Israel.

The TBIA Cancer AI blood testing platform leverages Fourier-transform infrared (FTIR) spectroscopy biochemical analysis of blood plasma and peripheral blood mononuclear cell (PBMC) components to distinguish between healthy subjects and patients with cancer.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in